glp 1 google scholar The expanding benefits of GLP-1 medicines Microbial regulation of GLP-1 and
Description
Rising diabetes and obesity prevalence, strong clinical outcomes, patient awareness, insurance coverage, and demand for effective, convenient metabolic therapies drive growth

MCH AIDS

Sandoz has been told its submission doesn't yet meet requirements and needs additional data pushing its expected launch from early 2026 to Q3 2026 at the earliest

Cardiovascular and metabolic effects of ghrelin

DPP-4 inhibitors are not recommended for cardiorenal risk reduction in high-risk individuals

Significant vomiting or diarrhoea can lead to dehydration and potentially acute kidney injury, so maintaining adequate fluid intake is important
